it will go to the fda. if it follows the path of pfizer and moderna, the fda will decide on saturday, cdc get ahold of it sunday and they will basically recommend either sunday or monday. so by and mod we'll know if this is good to go, which by all indications it will be, and then both johnson & johnson will start shipping it out, shots in arms immediately after that. it wouldn't be surprised to see shots in arms by tuesday. >> this is a global pandemic. we need it taken care of everywhere if we want to stop it here. how different is it, how important is it that this is a single-shot vaccine, especially in terms of getting to remote communities in the u.s. and globally? >> stephanie, you bring up a great point. what i always talk about, you can have herd immunity in your community but if the community next door doesn't have it, nobody has herd immunity and that goes for the globe as well. we need to make sure around the globe. in some areas, especially areas where they're more rural, don't necessarily have

the fda has just now given the green light to pfizer to ship and store its coronavirus vaccine at warmer temperatures than previously required after the company submitted new data. that move is expected to have a significant impact on availability across the country. we're also following new developments in the congressional hearings on the deadly january 6th capitol siege. 50 days ago today, the acting u.s. capitol police chief telling angry lawmakers that the department did not follow protocols largely because officers were simply overwhelmed. she also warned that militia groups involved in the insurrection want to, quote, blow up the capitol. and president biden addresses a joints session of congress. also tonight, the annual conservative political action congress begins in orlando with the false claims about the 2020 election playing a prominent role on the agenda and those lies are still backed up by a sizable number of house and senate republicans. cnn spoke to some who are simply refusing to debunk those lies. let's begin with the disturbing new details emerging from today's heari

the fda will then make a decision whether to accept that recommendation. but we do have that on the horizon. it is exciting to think about a third vaccine product being available, specifically because it is a one-dose vaccine, and that has such important logistical implications. but i'm worried today about the reporting that i have seen that their production is behind. part of the reason i was excited for the johnson & johnson vaccine, we talked about this last time, is because it seemed like their production capacity was really robust, they'd be able to make a ton of this. are those numbers coming in in a way that is disappointingly low? >> we are working very hard on that. on january 20th, the president instructed us to procure 200 million extra doses. that was pfizer and moderna, and as you said, that adds up to 600 million doses by july 31st. and i can tell you, the president instructed us to do everything possible to accelerate the delivery of johnson & johnson vaccines. and that's what i'm working on day and night. >> they have said, and the administ

that's being reviewed repeated the fda with u.s. data and on february the 26th the fda will consult with their independent advisory committee and we should be hearing from them soon. with regard to the astra seneca and the novavax those trials are both fully enrolled. these are event driven decisions so when they reach a certain amount of events they will then look at the data and make decisions as to whether or not to go ahead. having said that let me just now very briefly address the question that is a very relevant question that we are now more commonly being asked. if you look at the existing trials those that authority got in the eua and those that we anticipated hope will give the eu way when will we be able to say we can vaccinate children? children in the high school range and children in the elementary school range. you know from pfizer that they started off with the trial of 44,000 individuals down to 16-year-olds and then progress to down to 12-year-olds. so what they are going to be doing in april, starting in april, the

the fda is going to do a careful review. once this vaccine becomes widely available -- it's easy to store, a single shot -- i think it's going make a big difference. >> also, there is concern about what could be on the horizon -- dr. fauci and others warned for some time now that the uk variant could become the dominant variant right here in the u.s. and within weeks. we know that variant and others already detected in more than 30 states now. are we essentially in a race against time to get the first shot in the arms of americans to try to slow down the spread and keep these variants from evolving even more and perhaps get around the vaccine at some point? >> absolutely, we are definitely in a race. i'm confident these vaccines will hold up to the variants. but i'm deeply worried that if the variants take off and end up infecting a lot of people we could see the hospitals strained again. so we have got to push hard to get these vaccines out to especially high risk people. >> the number of new cases is down, which is encoura

>> the way this works is that we, the fda makes a recommendation to the fda. the fda considers that recommendation. then it goes to the centers for disease control and prevention through their committee, advisory committee for immunization practice, will determine are there specific groups that may best benefit from this vaccine? that will probably happen on sunday. by the middle of next week, probably by march 2nd or 3rd, this vaccine would start rolling off the shelves to the american public. >> what's your reaction, sanjay, to the major development in the fight against this virus? >> well, you know, it's been quite a year, right? a year ago, one year ago today, you know, we were talking about the beginning of this pandemic and the idea of a vaccine, let alone three. i don't think, really -- i don't think anybody sort of anticipated that we would move that quickly, that it could be done that quickly. so, it's really -- it's encouraging. you know, obviously there's been so much disspiriting news over this past year, wolf. the numbers on the right side of the

johnson & johnson's single shot vaccine, fda approved it. where do we go from here? >> i don't want to give you all the answers, don't want to give away two truths and lie. but it was exciting for everyone to see that alert that independent review committee gave the green light to the johnson & johnson vaccine by 22-0 vote. which is unanimous. they said long story short this one-shot vaccine checks all the boxes it needs to get out and get into the arms of americans. >> such great news of the rollout and hopefully many more people can get vaccinated very soon. now what you just alluded to, dr. patel. this is my first time in two truths and a lie. watching on facebook, help me out, i might need it. dr. patel is going to read three statements, one not true. comment on which you think is false. take it away, doc. >> we have to switch it up. i can't tell if you're nervous or not, but i have faith in you. >> little bit nervous right now. >> which is not true. a, fda suggested a single-dose vaccine may also reduce asymptomatic transmission. b, the cdc's acip committee will

it comes days after the fda reviewed it safe and highly effective. it found johnson & johnson's single dose shot to be 86% effective against the coronavirus virus. joining me from the lab producing these vaccines in anticipation of fda approval, tom costello. so talk to us about what is happening at this committee meeting so far and how likely the vaccine is to get approved today. >> reporter: i think it is almost a done deal. this is a little bit of a pro forma step but a very important step. we went through this with pfizer and also moderna. this is an outside group of experts and their job is to look at all the fda data, all the data that was submitted as well from johnson & johnson. with the pfizer faction, you may recall back in the fall, there were several cases of people having severe anaphylactic responses to the pfizer vaccine so that became a conversation topic. do you in fact give it to, for example, adolescents and teenagers? all of that is fodder for the conversation. in the case of this j & j vaccine, the numbers are good. it is 86% eff

same data being discussed at fda's advisory meeting. then acip will make recommendations for the use of the vaccine. i will stand by to review them and ready to sign. having an additional safe and effective vaccine will protect more people faster. i look forward to the acip discussion, receiving their recommendations and sharing with you about acip's recommendations and our next steps moving forward. thank you. i look forward to your questions. i will turn things over to dr. fauci. >> thank you very much, dr. walensky. i'm going to give now a brief update on the science, particularly focusing on the vaccine. if i can go to the first slide. this is the slide that i have shown to this group before. just building on what dr. walensky just said. we really are looking forward with very positive anticipation to the final determination of the fda concerning the johnson & johnson vaccine. what this means from the data we looked at that we now have three highly effective vaccines. importantly, each of them are very effective against severe disea

at this minute, this fda advisory panel is meeting about a potential new vaccine. this is the vaccine from johnson & johnson. instead of two doses, it's one. this panel's final recommendation is a critical

between 10 or 15,000 doses instead of being given out, they have to be thrown out. >> reporter: the fda says its rule against pulling covid vaccine is an infection measure. crossed contamination using the same needles and syringe have occurred other medications when this practice was utilized pharmacists say there are protocols in place they're urging the fda to change its position >> it is heartbreaking and makin me sick to my stomach knowing how many people still need the vaccine. >> reporter: many are still waiting for their turn without time or vaccine to spare. catie beck, nbc news, fairfax, virginia >> visit the plan our vaccine tool on our website. >>> nasa releasing new video of perseverance touching down on mars tro >>> a childhood cancer survival revealed she will be apart of the first space mission. she lost part of her legs to cancer and was treated at saint jude's, hayley arceneaux will join three others on the spacex-flight later this year. >> this mission is going to allow these kids to look towards the future and show them what's possible and survivorship can look like a

first is the fda. it could pave the way for the first single-dose vaccine and the president's first landmark covid relief bill hitting a major setback hours before the house votes on it. want to brain better? unlike ordinary memory supplements— neuriva has clinically proven ingredients that fuel 5 indicators of brain performance. memory, focus, accuracy, learning, and concentration. try our new gummies for 30 days and see the difference. covid's still a threat. and on reopening schools, we know what happens when we don't put safety first. ignore proper ventilation or rates of community spread, and the virus worsens. fail to provide masks or class sizes that allow for social distancing, and classrooms close back down. a successful reopening requires real safety and accountability measures. including prioritizing vaccines for educators. parents and educators agree: reopen schools. putting safety first. to defend against dark forces attacking your organization, you need to see in the dark. to have the w

the fda acknowledging for the first time that the vaccine is safe and effective against coronavirus, and data hinting it might prevent asymptomatic infections. fda officials meet friday to consider the emergency use authorization followed monday with the cdc, which means, this vaccine could be ready to roll out next week. johnson & johnson has pledged 20 million doses, but says it is prepared to immediately ship nearly 4 million doses as soon as it gets approved. today the white house says it's ready to go. >> while we await the fda's decision we want the american people to know that we're doing the work so that if the eua is granted we will waste no time getting this life-saving vaccine into the arms of americans. despite all of the temporary weather-related delays, our seven-day average daily doses administered is at 1.4 million. and we've already caught up on the weather-related shipping backlog. >> an emergency room condition and executive director of the committee to protect medicare. doctor davidson. g good to see you. could be roughly 4 million johnson & johnson vaccines shipp

eliquis is fda-approved and has both. what's next? i'm on board. don't stop taking eliquis unless your doctor tells you to, as stopping increases your risk of having a stroke. eliquis can cause serious and in rare cases fatal bleeding. don't take eliquis if you have an artificial heart valve or abnormal bleeding. while taking eliquis, you may bruise more easily and it may take longer than usual for any bleeding to stop. seek immediate medical care for sudden signs of bleeding like unusual bruising. eliquis may increase your bleeding risk if you take certain medicines. tell your doctor about all planned medical or dental procedures. ask your doctor about eliquis. and if your ability to afford your medication has changed, we want to help. your grooming business is booming. you need to hire. i need indeed. indeed you do. the moment you sponsor a job on indeed you get a shortlist of quality candidates from a resume data base. claim your seventy-five-dollar credit when you post your first job at indeed.com/groomer >>> moments from now we're standing by

the fda meeting now to discuss johnson & johnson's vaccine. what makes this shot different than the others. >>> and an east bay school district wants to bring sturn s backs to school next month and the plan to vaccinate more teachers could make in person learning safer. >>> a look at the new technology that could help firefighters during peak wildfire season, when high winds and rough terrain can make the fire fight difficult. >>> good morning, everybody. we made it to friday. it is february 26th and we want to start with mike. good morning. >> good morning, kumasi, reggie, nice to see both of you. and thanks for joining us wherever you are. home, gym, tablet,phone,e' everywhere. here is a look at live doppler 7 and it is bone dry. let me talk about the visibility, there is a little bit of fog developing around half moon bay, four miles that's manageable. east bay hills, clear everywhere else. we'll have a ton of sunshine today, and heading back to the coast, that's where it is going to be windy. little bit of blowing sand on our beaches. you

the fda saying it is working to finalize emergency use authorization of johnson & johnson's single-shot vaccine. a panel of independent experts unanimously recommending the move. what to know this morning. >>> breaking overnight, the house has passed the $1.9 trillion recovery package moving president biden closer to a legislative victory and millions of americans closer to relief. what's in the bill? the on >>> the obamas speaking out on race in america. what former president obama now has to say about reparations and michelle obama gets candid. her message to young people tackling institutional racism head on. ♪ >>> head-turning hairstyles. a celebrity hairstylist giving us a home hair care reboot. we've got the top tips she shares with her a-list clients, how to tame your mane, plus, the easiest ways to groom before you zoom. ♪ when you're ready come and get it ♪ >>> and ready, set, eat with our one-pan game plan. how to serve up a mouthwatering meal on your trusty sheet tray. your new go-to dinner. the super easy recipe with even easier cleanup. >>> all that and more as we sta

getting fda authorization for emergency use. after advisery panel gave unanimous recommendation yesterday. this now paves the way for roughly 4 million doses to be shipped out as early as monday. 20 million by the end of march. >> there will be another major manufacturer, another major vaccine supplier to increase vaccine supply. which would result in a more rapid acceleration of the vaccine effort. >> j&j's vaccine requires one shot, roughly 70% effective at preventing illness and offers strong protections against variants. the efficacy from modern aire and fizers two-dose vaccine is 957%. health experts say all three vaccines work. >> we in public health are not at all concerned about the differences in effectiveness of these various vaccines. >> reporter: but even with another vaccine option, a warning from the cdc about declining infections and hospitalizations. >> the latest data suggests that these declines may be stalling. potentially leveling off at still a very high number. >> dr. anthony fauci stressing the urgency of

the fda green lighting johnson & johnson's single shot version, a big boost for the nation's reinforcements, but when will they arrive and the important differences to getting the united states one step closer to immunity. it's sunday, february 28th. i'm liz kreutz. we'll have everything you need to know about the the johnson & joson vaccine in a moment. first a quick look at the weather with lisa argen. good morning. >> good morning. it's certainly chilly, a clear start out there this last day of february. live doppler 7 seeing that dark area offshore. that's our big ridge of high pressure that kept us so dry this winter. it's building in today. we'll see about 50 in vallejo. and numbers are running anywhere from the 30s to the 50s due to the upper elevation winds. 38 in san ramon. 47 in oakland. the and winds have been anywhere from 30 to 35 miles per hour above 1,000 feet. so with that, the variety of morning temperatures and we're warmer, four to five degrees warmer in the inland valleys. 12 degrees warmer than yesterday by the delta. plenty of sunshine throughout the day. temperatures

that's the sort of data that the fda is going to pay attention to. their bar for the emergency use authorization is do the benefits outweigh the risks? as simple as that. one other data point i want to show you, erica, because you and i have talked about this before. we know the vaccines protect against illness. it's been a long-standing question. do they help prevent you from getting inforgeted? what they found is people who received the vaccine were far less likely, 70% likely to have asymptomatic infection, so that kind of means that it seems to be protective to some extent against people actually carrying the virus. you remember, even if you're vaccinated you still have to wear a mask. why? you could be carrying the virus and spread it. this data seems to suggest that this should ultimately address that issue as well. >> which is exactly what we want to hear moving in that direction. there's also a new model that we've looked at so much over the last year or so, the new model showing cases and deaths are actually falling faster than expected. i k

now weeks later and this new fda report tonight just as encouraging. let's just reiterate here, 86% effective against severe illness here in the u.s. 100% effective at preventing hospitalizations and death. a single shot. doesn't have to be stored at those deep freeze temperatures. normal refrigeration. so, i guess the question tonight is, is this a game changer? >> david, thank you for having me back. it's wonderful news. it is just one more piece of really good news on the vaccine front. i think it's going to make an enormous difference. it's going to be so much easier to store and get out to people. and look, what we care about most is those hospitalizations and deaths. and this vaccine seems terrific at preventing that and that's what matters. >> and dr. jha, we obviously just don't know how this could effect the ultimate timeline for vaccinating americans, and no one wants to overpromise here. but let's look at what we do know tonight. pfizer and moderna have both promised to meet that deadline of 300 million doses each by the end of july. that's

one, such as remdesivir has gained fda aproved. its effect is clear but modest. with regard to getting early intervention monoclonal antibodies, both from lile and regeneron have received emergency use authorization. here again the earlier one uses these the better. these are as efficient and more efficient in those individuals who don't necessarily have a good antibody response. the same can be said of convalescent plasma which has also earned an emergency use authorization. again, because of the variability in the tighter of anti-bodder and various plasma alliquots. the issue here is getting this as early as possible. there's been a number of trials of a variety of antivirals or other agents that are off the shelf that have not been targeted. i'll get to targeted intervention in just a moment and hyperimmune globulin is also in clinical trial, and we await results of all of these. with regard to therapeutics for advanced disease, as i mentioned that is generally aimed at blocking an aberrant inflammatory or immunologic response as well as other pathogenic mecha

cody misener, a member of that fda vaccine advisory committee. also with us, cnn's chief medical correspondent, dr. sanjay gupta. dr. misener, what questions do you still have? what do you need to see today? >> well, i think what's very important, alisyn, is that we need every tool we can possibly get to curtail the spread of this pandemic. as you know, thousands of americans are dying on a daily basis. so we need a safe and effective vaccine. and we need the more vaccines that become available, the better. >> there had been some concern, with any vaccine, there's always concerns with side effects or reactions, and bell's palsy had come up as an area of concern with the johnson & johnson vaccine. what are you looking for there? what questions do you need answered? >> bell's palasy is a neurologi issue that relates to movements of the face. it's a -- there's no increased association. the calculations have been carefully performed by the fda and there's no evidence of an increased risk at this time of bell's palsy following either moderna the pfize

offit, that the fda is working now to put a plan in place to deal with the new variants. basically, as these variants become more dominant, and maybe vaccines not as effective against them, the fda is trying to put a system in place to handle that. what exactly wdoes that mean? what would they do or change going forward? >> here's when a line gets crossed. a line gets crossed when you have people who have received two doses of the vaccine that nonetheless are hospitalized with disease caused by one of these variants. that's when you know that we need that second generation of vaccine. the question is, how are you going to work on that second generation of vaccine in terms of allowing it to be used, say, through eua. and i think the more likely model will be the influenza model. where the vaccine would have to be tested to make sure that it's safe in a few hundred people and it induces the immune response you think it should induce to protect you. but you're not going to ask for another efficacy trial like the moderna trial of 30,000 people or the pfizer trial of 44,000 pe

david kessler, former fda commissioner, now the chief science officer for the covid-19 response under president biden. thank you for helping us understand this, sir, and i'm glad we came back around to talk to you about it, because this is really important thing. >> thank you, rachel. >>> all right, we'll be right back. again, i'll tell you that website that dr. kessler mentioned, combatcovid.hhs.gov about monoclonal antibody treatment. we'll be right back. ♪ ♪ (quiet piano music) (loud music & noises) ♪ ♪ (quiet piano music) comfort in the extreme. the lincoln family of luxury suvs. feeling sluggish or weighed down? it could be a sign that your digestive system isn't working at its best. taking metamucil everyday can help. metamucil psyllium fiber gels to trap and remove the waste that weighs you down. it also helps lower cholesterol and slow sugar absorption to promote healthy blood sugar levels. so you can feel lighter and more energetic. metamucil. support your daily digestive health. take the metamucil two week challenge and feel lighter and more energetic. sign up today

for distributing the latest johnson & johnson vaccine once it is approved for emergency use by the fda. this runs 35 minutes. >> by acknowledging that we have passed a grim milestone in this pandemic, half a million people debt from covid-19. this pandemic has touched each of us. so many have lost loved ones. we have been separated from our friends and families. too many of our businesses and schools have been closed for way too long. president biden is clear, we are at war with this virus, and we are using every resource at our disposal to defeat it. we are keeping equity at the front and center of our response , partnering with states, tribes, and territories to increase vaccinations in the hardest hit and hardest to reach communities. increasing supply to convenient and trusted locations like community health centers, deploying mobile units to meet people where they are, and improving data collection so that we have a better understanding of the inequities currently experienced. today, we are announcing another action we are taking to ensure an equitable response. in the month of ma

again, the final decisions, we always leave to the fda. i'm trying to give you a road map of what likely will happen, but then also, with the studies that i just mentioned, to getting the information to make the decision in elementary school children almost certainly will not be firmed down until the first quarter of 2022. i will stop there and hand it back to andy. andy: thanks, dr. fauci. okay. we can take some questions. >> all right. >> thanks for taking the question. i have a question about the federal mass vaccination sites and how you're determining where to set this up. how much of this is estates -- states coming to you and saying, okay, we need help with this place, that place. can you come in and set up a fema site? how much is it you saying to the state saying, we think you need some help here, and we see the progress, you are not hitting enough of the underserved communities, so we want to do a site here, and in general, has there been kind of a 50-state overall assessment of how the states are doing on distribution and where

fda that this be approved. and we went through this same process with moderna and pfizer. so maybe even late friday we may hear that there's an authorized now emergency use authorization for the johnson & johnson vaccine. over the weekend, we will likely hear from the cdc committee that actually looks at these immunization protocols and they'll make the recommendations on the who, what, where. who should get this vaccine, where should it go, all that sort of stuff. and then i've talked to folks at johnson & johnson. there are a certain number of doses currently available. to your question, i guess, early next week they could probably be shipping out. >> two questions here, sanjay. one, i thought i had understood that from this data they were going to get some sign or at least ask about transmissibility, whether or not there was any indication about whether the johnson & johnson vaccine had an impact on transmissibility, whether you could get it and be asymptomatic. and also as we look at this data, it confirms

last month the fda said they needed more data, and they delayed their decision from march to june. there was an fda panel of outside experts that wanted evidence for the treatments, but the investors are still holding out hope in part a because of the unusual way that the company and regulators collaborated and also the fact that, you know, treatment has been elusive, so everyone wants to find something that could work. analysts think an approval could help push biogen's stock up as much as 70%. the drug could bring in the $10 billion in sales a year. of course, the risk is to the downside as well. if there is no approval, especially because biogen's other drugs are facing competition from some rifles. jack: erik shah, very important story. thank you for doing that, and i'm glass at -- glad the tasha, did you know geico could save you hundreds on car insurance and a whole lot more? hmm. so what are you waiting for? hip hop group tag team to help you plan dessert? ♪ french vanilla! rocky road! ♪ ♪ chocolate, peanut butter, cookie dough! ♪ ♪ scoop! there it is! ♪ ♪ scoo

the new calls to the fda to change its position on one practice known as vaccine pooling. we're going to dive in. (vo) ideas exist inside you, electrify you. they grow from our imagination, but they can't be held back. they want to be set free. to make the world more responsible, and even more incredible. ideas start the future, just like that. fine, no one leaves the table until your finished. fine, we'll sleep here. ♪♪ it's the easiest because it's the cheesiest. kraft. for the win win. visible is wireless that doesn't play games. it's powered by verizon for as little as $25 a month. but it gets crazier. bring a friend every month and get every month for $5. boom! 12 months of $5 wireless. visible, wireless that gets better with friends. ordinary tissues burn when theo blows. so dad bought puffs plus lotion, and rescued his nose. with up to 50% more lotion puffs bring soothing softness and relief. a nose in need deserves puffs indeed. >> vo: my car is my after-work decompression zone. ♪ music ♪ >> vo: so when my windshield broke... i found the experts at safelite

7 news reporter kate larson is part of our vaccine team, and she spoke with a voting member of the fda review committee about concerns and what comes next. >> reporter: a third covid vaccine is close to authorization. >> it's been a remarkable year in terms of science. >> reporter: dr. halle gantz is a member of the advisory committee. she said they met twice a year to discuss the plu vaccine, now, three times in three months to approve pfizer, moderna and now johnson & johnson. >> this will set the fis look at vaccinations in the future. >> reporter: johnson & johnson is one shot, and it will be stored in a refrigerator up to three months, and the other vaccines need to be kept in ultra cold freezer the efficacy rate is 86%. the other to are 92 and 94% effective. >> how long will the immune response last and if we need boosters. >> reporter: pfizer and moderna, they are already modifying vaccines toment testing a third booster shot of the regular formulas. >> we may see that everybody needs to get a booster. right now, the vaccines are working really hard against the strains that are

former fda boss dr. scott gottlieb tweeted after her appointment, she will represent the fda's prerogatives well in a time of crisis and advance the interest of consumers and patients. she spoke to me about the way the fda was gearing up together with the nih to fight the emerging variants which dr. collins called a shape shifting. >> as far as we know right now, the vaccines we have of the united states will have sufficient efficacy against the variants that has been identified and tested. including the south african variant. we have known that the variants most likely would occur and we have been planning for how to deal with it. >> dr. woodcock told me if they have to adjust the vaccines to account for a new variants, they would look at the data and also direct guidance to the manufacturers without having to go through more large clinical trials. shannon? >> shannon: dr. siegel, thank you very much. president biden will reportedly move to revoke one of his predecessor signature policy, medical work re

within the hour the fda approved johnson & johnson's single dose emergency vaccine for emergency use. it will be the third vaccine to help us fight covid in this country. doses could roll out as soon as monday and it could change the game. it's one shot and can be stored in the kind of refrigerators america's medical community most commonly uses. this approval comes at a critical moment. states are facing vaccine shortages but shortages in shots can be viewed as a good thing because it means americans are getting them. at this hour more than 96 million doses have been delivered, over 72 million hots deliver. new cases across america have dropped but it is not time to more on. as ron klain says on twitter, we are making progress on vaccinations and other interventions against covid. but we need people to continue to mask and social distancing what we're doing is working. we could have made this progress many, many months ago but we did not. half a million americans and their families have paid the price. the past month has proved governing can work. it just gave us some light at the en

meg tirrell with latest from the fda. >> good morning. this morning the fda released the documents ahead of the advisers who at the end of the day are going to vote on it. the documents are a first look at what the regulator thinks about the vaccine. looking at the graph, the protection is the blue line there really kicking in after two weeks after the shot. of course, this is a one-shot vaccine, an unlike the mrna vaccines you don't have to wait three or four weeks for the second shot to have the protection kick in. it is one and done here. and so unlike what we saw with the clinical results in janway, completely protective against hospitalization and death even though we saw different efficacy in regions like south africa, there was not that protection in the virology there. and so there was no preclusion to the emergency use authorization, and the kinds of reaction is injection site pain, and fatigue, and headache and muscle pain. and so in some cases there were some people getting hives after the shot, and one hypersensitivity reactio

again, the final decisions, we always leave to the fda. i'm trying to give you a road map of what likely will happen, but then also, with the studies that i just mentioned, to getting the information to make the decision in elementary school children almost certainly will not be firmed down until the first quarter of 2022. i will stop there and hand it back to andy. thanks, dr. fauci. andy: -- andy: thanks, dr. fauci. okay. we can take some questions. >> all right. >> thanks for taking the question. i have a question about the federal mask vaccination sites and how you're determining where to set this up. how much of this is estates coming to you and saying, okay, we need help with this place, that place. can you come in and set up a fema site? how much is it you saying to the state saying, we think you need some help here, and we see the progress, you are not hitting enough of the underserved communities, so we want to do a site here, and in general, has there been kind of a 50-state overall assessment at how states -- of how the states a

>>now it's 60 long wait for a 3rd covid-19 coming to an end apparently after an fda panel endorses the single shot vaccine from johnson and johnson good evening, everyone and welcome thanks for joining us on kron 4 news at 6. i'm catherine heenan pam has the night off and i'm ken wayne, the single those shots are expected to get final fda approval over the weekend. >>and governor newsome says the federal government plans to send more than a million johnson and johnson doses to california by the end of next month and kron four's dan kerman has been following the story joins us on live from san francisco with the latest dan. >>well the good news is in addition to more johnson and johnson vaccine. he says the allocations of pfizer and moderna also being up then that means they are likely to expand eligibility sometime in the next few weeks. friday afternoon, the johnson and johnson covid-19 vaccine had not yet received its final fda approval. but that didn't stop the governor from announcing more than a million doses of we'll be coming to california over the next 3 weeks we anticipate rec

it is going up for review at the fda with an advisory meeting february 26th. it could be coming quickly to the market potentially we pressed him on what type of supply they expect to see for the vaccines at first. he reiterated 100 million doses they hope by the end of june here's what he said about vaccine supply overall. >> i am growing increasingly optimistic between assuming that, again, we get the thumbs-up from the fda you combine that with the increased numbers that are being produced by pfizer and moderna, and those will result in significant differences that hopefully will alleviate a supply issue over the second quarter of 2021. >> now, of course with johnson & johnson potentially coming on the market even as soon as early march, we also talked with walgreens head of pharmacy and health care rick gates who said he expected widespread availability of covid vaccines in their pharmacies by the end of march and early april we also talked about the potential that we will be getting covid shots for years to come because of variants or how long the protecti

. >> and the johnson & johnson vaccine, it heads to the fda this week with news expected by tomorrow morning, right? what can you tell us >> tomorrow morning we get to see the results of the fda's own analysis of the j & j clinical trial data remember, we saw at the end of january that single shot was 72% effective in the u.s. and completely prevented hospitalization and death from covid. now, key questions we may get answers to in these documents. did variants in the u.s. effect the efficacy will there be any clues to whether the vaccine can reduce transmission the fda's advisers meet friday to discuss the data and vote if all goes well, we could see the third vaccine authorized in the u.s. as soon as this weekend, shep. >> all right meg tirrell, thank you >>> dr. kavita patel now, nbc news contributor, white house health policy director under obama. thank you for being here the big news out of today's hearing, more doses expected across the board, including 20 million from johnson & johnson by the end of march once that vaccine is approved. how big of an impact could all of this ha

johnson & johnson's covid vaccine granted emergency use authorization by the fda. how soon the shots could be available. plus, the possible shot in the arm for the economy. the covid relief package now in the senate's hands. >> if we act now decisively, quickly and boldly, we can finally get ahead of this virus. >> could kamala harris cast a deciding vote in a divided chamber? >>> return to the spotlight. president trump making his first public appearance since leaving office, speaking before a major conservative group. what he's expected to say to his supporters and what this means for the control of the republican party. >>> new accuser. a second sexual harassment allegation against new york

last month the fda said they needed more data, and they delayed their decision from march to june. there was an fda panel of outside experts that wanted evidence for the treatments, but the investors are still holding out hope in part a because of the unusual way that the company and regulators collaborated and also the fact that, you know, treatment has been elusive, so everyone wants to find something that could work. analysts think an approval could help push biogen's stock up as much as 70%. the drug could bring in the $10 billion in sales a year. of course, the risk is to the downside as well. if there is no approval, especially because biogen's other drugs are facing competition from some rifles. jack: erik shah, very important story. thank you for doing that, and i'm glass at -- glad time to start brushing with parodontax toothpaste? if your gums bleed when you brush, the answer is yes. the clock may be ticking towards worse... parodontax is 3x more effective at removing plaque, the main cause of bleeding gums parodontax i knew about the tremors. but when i started seeing th

>>we always leave to the fda. >>and as the fda continues to evaluate the country's 3rd coronavirus vaccine. the white house is opening more community vaccination centers. the team did just announced today 4 in florida and one in pennsylvania that will be able to vaccinate thousands of people every single day once up and running live in washington. i'm jessi jesse supply certainly is needed. we know pfizer moderna where one into where does. >>the 3rd coronavirus vaccine stand right now. yeah the johnson and johnson shot is going to be going before the fda officially for its emergency use authorization test you could say. >>next friday, the 26th and so if approved this will be major going forward in terms of availability of the vaccine because this would be the country's first single that shot, and so that's why the white house is kind of doing this you know wait and see because it will impact a lot of its projections moving forward to being able to vaccinate americans probably a lot faster. >>all right jesse, let's

the data are now with the fda. they are examining it. they have scheduled the advisory committee, the vaccines and related advisory committee which will meet in three weeks. let me review for you where we are and where we hope to go. as you know, the data on efficacy of this ensemble trial, which involved three countries, the united states, brazil and the republic of south africa, showed an overall efficacy of 66%. when you unpacked from the different countries, you had a 72% efficacy for mild to moderate disease in the usa, in the republic of south africa, which is of concern to us because of the mutant and the lineage that's dominant in the republic of south africa, namely the b-1351. the protection against moderate disease was 57%. the good news is that when you look across all of the countries, the protection against truly severe disease was well over 80%. in fact, about 88.8%. also of interest is that in the south african study as well as all of the others, there were essentially no hospitalizations or deaths. the sobering news is t

johnson & johnson is expected to get its fda authorization as soon as today. it says the cdc reports about 9% of all americans are fully vaccinated. trevor olt has what's being done to prepare for the boost. >> reporter: this morning, a game changing boost in the vaccine race. the fda is working rapidly to finalize emergency use authorization of the johnson & johnson single shot vaccine. >> it is a single dose regimen. >> reporter: a panel of experts recommending authorization friday after trials have shown the johnson & johnson shot is 85% effective against severe disease and 100% effective against hospitalization and death. with two out of 400,000 trial participants reportedly having suspected severe allergic reactions. doses can be stored and shipped in normal refrigerators. upon authorization, the 3 to 4 million doses already available could start to ship out as early as monday. with a goal of 20 million by the end of march, and 100 million by june. >> we have three highly effective vaccines. you look at the data and it is clear that you get essentially no

if the full fda grants approval it would give americans access to three vaccines. but it is a race against the clock, as new variants emerge. charles watson is live in atlanta with more on that. charles. reporter: good evening jon with final approval for emergency use authorization, in the works, johnson & johnson is expected to hit the ground quickly with its new covid-19 vaccine as many as 4 million doses could be shipped out to states as early as monday putting a third vaccine in the mix in the fight against covid-19. >> what this means from the data we looked at that we now have three highly effective vaccines. importantly, each of them are very effective against the disease and virtually all of them say that you look at the data and it is clear that you get essentially no hospitalizations or deaths. reporter: with an efficacy rate of 72% in the u.s., johnson & johnson vaccine doesn't offer quite as much protection as others on the market, however, unlike competitors it vaccine requires one shot and can be stored at warmer temperatures. while johnson & johnson

7 news reporter kate larson is part of our vaccine team, and she spoke with a voting member of the fda review committee about concerns and what comes next. >> reporter: a third covid vaccine is close to authorization. >> it's been a remarkable year in terms of science. >> reporter: dr. halle gantz is a member of the advisory committee. she said they met twice a year to discuss the plu vaccine, now, three times in three months to approve pfizer, moderna and now johnson & johnson. >> this will set the fis look at vaccinations in the future. >> reporter: johnson & johnson is one shot, and it will be stored in a refrigerator up to three months, and the other vaccines need to be kept in ultra cold freezers. the efficacy rate is 86%. the other to are 92 and 94% effective. >> how long will the immune response last and if we need boosters. >> reporter: pfizer and moderna, they are already modifying vaccines toment testing a third booster shot of the regular formulas. >> we may see that everybody needs to get a booster. right now, the vaccines are working really hard against the strains that ar

the fda set the meeting for their external scientific advisory panel for february 26th. they took the data review and a few days afterwards the cdc has to have their meeting and final review and recommendation. so i would guess it would be somewhere by the end of february if it gets authorized by the fda that it would have the green light to be distributed and the vaccination can start soon after that. maybe the first week of march. >> okay. let's talk about global phase 3 trial data, the j&j vaccine efficacy against moderate and severe diseases. that was 66%. 72% in the u.s. 85% effective in preventing hospitalizations. are those numbers good? >> the numbers are really good. if you look at the prevention of death, prevention of hospitalizations, no one died in this trial that got the vaccine. no hospitalizations. over 85% of the people were protected from that severe, most severe disease. didn't go to the hospital. that's really fantastic. the other numbers i wouldn't get too mixed up about. they're as good, i think, as the numbers we would see from the other vaccines i